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In the majority of chronic lymphocytic leukemias (CLL), proliferative B lymphocytes are thought to be frozen in vivo at a given maturation stage (1) . Recently, several studies have emphasized that CLL cells could be driven to differentiate into plasma cells in vitro (with or without proliferation) upon triggering by mitogens (2, 3, 4) or T cell-derived factors (5, 6) . Thus far, however, no study has been designed to elucidate whether leukemic B cells can be triggered by T cell-derived iymphokines that are known to induce normal B cells to proliferate. In preliminary experiments, we found that leukemic B cells from six of nine CLL patients, when stimulated with anti-~ antibody and/or with Staphylococcus aureus Cowan strain I (SAC), proliferate in the presence of various T cell-derived conditioned media, which potentially contained a number of lymphokines (unpublished data). Absorption experiments suggested that interleukin 2 (IL-2) was a potent growth factor for these leukemic B cells. We report here that purified recombinant IL-2 is indeed able to induce leukemic cells from some patients to proliferate. These data, obtained with monoclonal populations of B cells, which are likely free of contaminating T cells, provide further evidence that IL-2 can trigger activated B cells to proliferate.
Material and Methods
Isolation and Characterization of Lymphoid Cells. Nine cases of well-documented B cell CLL were studied. Mononuclear cells were purified from blood by centrifugation on a Ficoll-Hypaque (Pharmacia Fine Chemicals, Uppsala, Sweden) density gradient. Although the percentage of E-rosetting cells was very low (~<1% except in patient ROS) B cells were purified by one or two cycles of depletion by Ficoll-Hypaque centrifugation of those cells forming E rosettes with 2 aminoethylisothiouronium bromide-treated sheep red blood cells. Cell marker studies showed that >99% of the cells were monoclonal B cells bearing surface IgM and IgD in eight cases, and IgG in one.
Normal B cells were purified from the spleen of a patient with idiopathic thrombocytopenic purpura. This B cell population contained <1% T cells and >95% surface Igpositive cells.
Monoclonal Microassay for IL-2 activity determination was performed on the IL-2-dependent murine cell line, CTLL, according to Gillis et ai. (7). We define one unit of IL-2 as the activity contained in a sample dilution yielding a proliferation equal to 50% of the maximum [3H]thymidine uptake (in cpm) of the first French Workshop standard IL-2 preparation (8). In these conditions, semipurified and recombinant IL-2 had an activity of 14 and 1,900 U/ml, respectively. Therefore, 1 U corresponds to 10.5 ng recombinant IL-2. One U IL-2 contained <0.05 pg endotoxin, as assessed by the limulus amebocyte assay.
Assay of B Cell Proliferation. Proliferation was determined after preactivation of B cell
by SAC or anti-# antibody. In the SAC assay (9), cells were cultivated at a concentration of 106/ml for 3 d in 250-ml flasks (1-53373, Nunc, Roskilde, Denmark), with or without SAC (1 : 10,000 vol/vol). SAC was prepared in our laboratory (killed by incubation in 1.5% formaldehyde, followed by heat treatment). This preparation has no mitogenic activity on purified T cells. At day 3 (unless otherwise specified) cells were washed three times in complete medium, and distributed at a cell concentration of 105 or 5 X 104 cells/well in 200 #1 medium, in 96-well, flat-bottom microtiter plates (67008, Nunc) with serial dilutions of purified recombinant IL-2 for three additional days.
In the costimulatory assay with anti-# antibody (10), a mouse IgG1 mAb against human # chains (prepared in our laboratory) was coupled to Sepharose CL 4 B (2 mg/ml) (Pharmacia Fine Chemicals) and used at a concentration of 1 #g/ml; this dose was selected on the basis of preliminary experiments on normal and leukemic B cells. 10 h leukemic, or 5 × 104 normal B cells were incubated in 200 #1 medium in microtiter plates, in the presence or absence of anti-~ antibody, with serial dilutions of IL-2 to be tested, for 3 or 6d.
In both assays, 1 #Ci/well [~H]thymidine ([~H]TdR) (Commisariat pour l'Energie Atomique, Gif-sur-Yvette, France) was added during the last 18 h of culture. Cells were thereafter harvested on glass fiber filters, and incorporation of [3H]TdR was measured by standard liquid scintillation counting.
Results and Discussion
The main result of this study is the demonstration that purified recombinant IL-2 is able to trigger leukemic B cells from six of nine CLL cases to proliferate after preactivation. The effect of recombinant IL-2 on CLL B cells was assessed in two different B cell proliferative assays, i.e. after activation by SAC or anti-#. IL-2 at various concentrations (0.01-3 U/ml) was added at day 0 in the costimulatory assay with anti-#, or at day 3 after preactivation by SAC. In the SAC assay, cells from three of nine patients proliferated in response to SAC alone: in two cases (ETA and ROS) the response was weak, with a peak at day 3; in the third case (BAU), the proliferative response was high, with a peak at day 6. Cells that responded to SAC (from the aforementioned three patients), proliferated in response to IL-2 (Fig. 1) . No response was observed among cells from the other six patients.
Costimulation of purified leukemic B cells with IL-2 and anti-# gave only a marginal response (<1,500 cpm) at day 3. When the incubation time was extended to 6 d, a clearcut pattern of IL-2 reactivity emerged in the leukemic cells (Fig. 2) . Interestingly, cells from one patient (PERI) proliferated to IL-2 alone, the response being enhanced after preactivation with anti-t~. The cells from four other patients (ETA, CAR, POU, and BAU) proliferated in response to IL-2 when simultaneously activated by anti-t~. Finally, no response was noted in three cases (HER, MEY, and PERO). Cells from patient ROS, which featured surface IgG and which proliferated in response to IL-2 after SAC stimulation were not studied in this assay. Cells from a single patient proliferated slightly in the presence of anti-~ alone; in the other cases, cells were preactivated without detectable proliferation, as actually occurs for normal B cells triggered by low doses of anti-~ (11). Of note, the CLL cell response to IL-2 peaked at day 6, i.e. later than the response of anti-t~-activated normal B cells to growth factors (11) . The amount of IL-2 needed for the leukemic cells to proliferate varied from patient to patient. In one case (POU), the cells were responsive only at high concentrations of IL-2 (3 and 1 U/ml), whereas in the other four cases (ETA, BAU, PERI, and CAR), the dose/response curves were similar, with a peak of ~1 U/ml, and background-level proliferation at a concentration of 0.02 U/ml. With regard to these results, it is noteworthy that our IL-2 assay on the murine IL-2-dependent CTLL line is able to detect ~0.01 U/ml IL-2.
The use of leukemic B cells makes it very unlikely that the observed effect was due to residual T or accessory cells. After one or two cycles of E-rosette depletion, the leukemic population tested was almost pure, i.e. contained >99% surface Igpositive monoclonal cells and <0.02% T cells, and <0.01% polyclonal B cells, as estimated by cell markers at day 0, 3, and 6 of culture. On the other hand, to exclude the possibility that the responsiveness to IL-2 was a unique feature of these leukemic B cells, we performed similar experiments on spleen-enriched B cell populations, Again, recombinant or semipurified IL-2 induced activated B cells to proliferate in a dose-dependent fashion (Fig. 3) . These results are in agreement with recently published data. IL-2 receptors have been found on ~25% of anti-u-or SAC-activated normal B cells (12, and our unpublished results). Herein, the study of IL-2 receptor expression by leukemic cells was hampered, in some cases, by nonspecific binding to a strong Fc receptor. However, fresh cells from two of six patients were weakly stained by anti-TAC; in one case, they proliferated in response to IL-2 without preactivation (patient PERI), and in the other case (BAU), a second signal, delivered either by SAC or anti-u, was needed for proliferation to occur. After activation by SAC or anti-u, the cells from two other patients, although responsive to IL-2, did not exhibit detectable amounts of TAC antigen, possibly because of a low density of receptor. Finally, in one case studied, anti-TAC was able to inhibit recombinant IL-2-induced proliferation of leukemic cells up to a 10 -5 dilution, providing further evidence that IL-2 is indeed the active lymphokine in our assay.
Altogether, our findings demonstrate that B cells from a majority of CLL, as well as normal B cells, are susceptible to IL-2. The role of IL-2 in B cell growth, so far, has been controversial. For instance, IL-2, together with two other lympbokines, was needed for mouse B cell proliferation and differentiation (13) ; human B cells preactivated by SAC were shown to proliferate in response to purified IL-2, in accordance with our results (12) . On the other hand, it has been reported (14, 15) that absorption of IL-2 from T cell-conditioned medium did not modify the proliferative response of activated normal B cells.
Although CLL B cells can differentiate, with T cell help, into plasma cells, we did not observe such an effect with IL-2. When IL-2-reponsive cells (four cases) were studied 3-12 d after SAC or anti-u preactivation, the majority of cells were large immunoblasts devoid of cytoplasmic Ig.
These results raise important issues on the possible in vivo role of physiologic lymphokines such as IL-2 on the growth of the leukemic clone. It is worth noting that in one case, cells were responsive to IL-2 without any preactivation; in other instances, it is conceivable that antiidiotypic antibodies directed against surface Ig may trigger expression of IL-2 receptors, thus leading to possible regulation or expansion of the leukemic B cell clone by IL-2.
Summary
The proliferative responses of purified leukemic human B cells from nine B cell chronic lymphocytic leukemias to recombinant interleukin 2 (IL-2), spontaneously, and after preactivation by Staphylococcus aureus Cowan I (SAC) or anti-u antibodies were studied. Three patterns of response were observed: (a) no response (three cases); (b) a moderate spontaneous response enhanced by anti-u (one case); (c) a high proliferative response after preactivation by anti-u and/or SAC (five cases). IL-2 could also trigger normal B cells, purified from spleen, to proliferative after preactivation by anti-u or SAC. These results provide evidence that IL-2 is a lymphokine that acts physiologically on both B and T cells.
